S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$103.96
+1.78 (+1.74 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$102.58
Now: $103.96
$104.82
50-Day Range
$80.49
MA: $90.08
$100.84
52-Week Range
$62.55
Now: $103.96
$104.82
Volume9.17 million shs
Average Volume9.72 million shs
Market Capitalization$183.54 billion
P/E Ratio21.98
Dividend Yield4.62%
Beta0.72
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.72 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900
Employees30,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.65 per share
Book Value$8.66 per share

Profitability

Net Income$7.88 billion

Miscellaneous

Outstanding Shares1,765,474,000
Market Cap$183.54 billion
Next Earnings Date2/5/2021 (Estimated)
OptionableOptionable
$103.96
+1.78 (+1.74 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABBV shares have increased by 22.5% and is now trading at $103.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AbbVie?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AbbVie
.

What stocks does MarketBeat like better than AbbVie?

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AbbVie wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, February 5th 2021.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Friday, October, 30th. The company reported $2.83 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.75 by $0.08. The company had revenue of $12.88 billion for the quarter, compared to analyst estimates of $12.71 billion. AbbVie had a return on equity of 439.24% and a net margin of 18.16%. The business's revenue for the quarter was up 51.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.33 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 30th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.30 per share on Tuesday, February 16th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 5.00%. The ex-dividend date of this dividend is Thursday, January 14th. This is a boost from AbbVie's previous quarterly dividend of $1.18.
View AbbVie's dividend history
.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has initiated a stock repurchase program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY 2020 Pre-Market earnings guidance on Friday, October, 30th. The company provided EPS guidance of 10.47-10.49 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.42.

What price target have analysts set for ABBV?

21 Wall Street analysts have issued 1 year price targets for AbbVie's stock. Their forecasts range from $95.00 to $127.00. On average, they expect AbbVie's share price to reach $111.00 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts' price targets for AbbVie
.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 12,840,000 shares, an increase of 20.7% from the October 15th total of 10,640,000 shares. Based on an average trading volume of 7,930,000 shares, the days-to-cover ratio is presently 1.6 days.
View AbbVie's Short Interest
.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 66, Pay $7.11M)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 54, Pay $3.98M)
  • Mr. Robert A. Michael, Exec. VP & CFO (Age 50, Pay $2.76M)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 57, Pay $4.3M)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 57, Pay $4.08M)
  • Dr. Azita Saleki-Gerhardt, Exec. VP of Operations (Age 57)
  • Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 58)
  • Ms. Elizabeth Shea, VP of Investor Relations
  • Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 54)
  • Mr. Scott C. Brun M.D., VP of Scientific Affairs & Head of AbbVie Ventures

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.91%), State Street Corp (4.43%), Nuveen Asset Management LLC (1.14%), Morgan Stanley (0.78%), Orbis Allan Gray Ltd (0.53%) and UBS Asset Management Americas Inc. (0.52%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, State Street Corp, BlackRock Inc., Orbis Allan Gray Ltd, Los Angeles Capital Management & Equity Research Inc., Federated Hermes Inc., and KBC Group NV. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
.

Which major investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, AJO LP, DekaBank Deutsche Girozentrale, CIBC Private Wealth Group LLC, Menora Mivtachim Holdings LTD., UBS Asset Management Americas Inc., PGGM Investments, and Lord Abbett & CO. LLC. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $103.95.

How big of a company is AbbVie?

AbbVie has a market capitalization of $183.52 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.